https://nova.newcastle.edu.au/vital/access/ /manager/Index ${session.getAttribute("locale")} 5 Delayed versus immediate cord clamping in preterm infants https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:33645 Wed 24 Nov 2021 15:51:52 AEDT ]]> How does progesterone relax the uterus in pregnancy? https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:16696 Wed 11 Apr 2018 16:57:04 AEST ]]> A surgical safety checklist (letter) https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:7997 Wed 11 Apr 2018 16:46:42 AEST ]]> Effect of aspirin or resistant starch on colorectal neoplasia in the Lynch syndrome https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:4498 Wed 11 Apr 2018 15:42:17 AEST ]]> Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:28543 Wed 11 Apr 2018 15:37:28 AEST ]]> Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:14865 Wed 11 Apr 2018 14:49:29 AEST ]]> A randomized trial of tenecteplase versus alteplase for acute ischemic stroke https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:13689 Wed 11 Apr 2018 12:02:09 AEST ]]> Adjuvant exemestane with ovarian suppression in premenopausal breast cancer https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:16287 Wed 11 Apr 2018 11:53:01 AEST ]]> Coverage by the news media of the benefits and risks of medications https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:2834 Wed 11 Apr 2018 11:47:59 AEST ]]> Letrozole therapy alone or in sequence with tamoxifen in women with breast cancer https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:8317 Wed 11 Apr 2018 10:31:35 AEST ]]> Rapid blood-pressure lowering in patients with acute intracerebral hemorrhage https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:14864 Wed 11 Apr 2018 10:29:15 AEST ]]> Docosahexaenoic acid and bronchopulmonary dysplasia in preterm infants https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:30962 Wed 11 Apr 2018 10:28:39 AEST ]]> Peginterferon and ribavirin for hepatitis C (letter) https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:4549 Wed 11 Apr 2018 10:25:52 AEST ]]> Short-course radiation plus temozolomide in elderly patients with glioblastoma https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:34579 Wed 09 Mar 2022 16:00:51 AEDT ]]> Tailoring adjuvant endocrine therapy for premenopausal breast cancer https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:32778 Wed 07 Feb 2024 16:54:46 AEDT ]]> Irritable bowel syndrome https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:34075 Wed 06 Feb 2019 14:24:00 AEDT ]]> Conservative oxygen therapy during mechanical ventilation in the ICU https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:48262 2) and have a high arterial oxygen tension. The conservative use of oxygen may reduce oxygen exposure, diminish lung and systemic oxidative injury, and thereby increase the number of ventilator-free days (days alive and free from mechanical ventilation). Methods: We randomly assigned 1000 adult patients who were anticipated to require mechanical ventilation beyond the day after recruitment in the ICU to receive conservative or usual oxygen therapy. In the two groups, the default lower limit for oxygen saturation as measured by pulse oximetry (Spo₂) was 90%. In the conservativeoxygen group, the upper limit of the Spo₂ alarm was set to sound when the level reached 97%, and the Fio2 was decreased to 0.21 if the Spo₂ was above the acceptable lower limit. In the usual-oxygen group, there were no specific measures limiting the Fio₂ or the Spo₂. The primary outcome was the number of ventilator-free days from randomization until day 28. Results: The number of ventilator-free days did not differ significantly between the conservative-oxygen group and the usual-oxygen group, with a median duration of 21.3 days (interquartile range, 0 to 26.3) and 22.1 days (interquartile range, 0 to 26.2), respectively, for an absolute difference of -0.3 days (95% confidence interval [CI], -2.1 to 1.6; P = 0.80). The conservative-oxygen group spent more time in the ICU with an Fio2 of 0.21 than the usual-oxygen group, with a median duration of 29 hours (interquartile range, 5 to 78) and 1 hour (interquartile range, 0 to 17), respectively (absolute difference, 28 hours; 95% CI, 22 to 34); the conservative-oxygen group spent less time with an Spo₂ exceeding 96%, with a duration of 27 hours (interquartile range, 11 to 63.5) and 49 hours (interquartile range, 22 to 112), respectively (absolute difference, 22 hours; 95% CI, 14 to 30). At 180 days, mortality was 35.7% in the conservative-oxygen group and 34.5% in the usual-oxygen group, for an unadjusted odds ratio of 1.05 (95% CI, 0.81 to 1.37). Conclusions: In adults undergoing mechanical ventilation in the ICU, the use of conservative oxygen therapy, as compared with usual oxygen therapy, did not significantly affect the number of ventilator-free days.]]> Tue 21 Mar 2023 17:42:53 AEDT ]]> Low-dose versus standard-dose intravenous alteplase in acute ischemic stroke https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:24860 Thu 27 Jan 2022 15:58:04 AEDT ]]> Pioglitazone after ischemic stroke or transient ischemic attack https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:24617 Thu 17 Feb 2022 09:26:56 AEDT ]]> Scorpion envenomation: reply https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:19774 Sat 24 Mar 2018 07:54:26 AEDT ]]> Functional dyspepsia https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:26272 Sat 24 Mar 2018 07:40:16 AEDT ]]> Endovascular therapy for ischemic stroke with perfusion-imaging selection https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:27444 Sat 24 Mar 2018 07:32:37 AEDT ]]> Tenecteplase versus alteplase for acute ischemic stroke: the authors reply (letter) https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:28518 Sat 24 Mar 2018 07:29:19 AEDT ]]> Goserelin for ovarian protection during breast-cancer adjuvant chemotherapy https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:27579 Sat 24 Mar 2018 07:23:42 AEDT ]]> A phase 3 trial of sebelipase alfa in lysosomal acid lipase deficiency https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:22878 Sat 24 Mar 2018 07:12:59 AEDT ]]> A Phase 2 Trial of Sibeprenlimab in Patients with IgA Nephropathy https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:54017 Mon 29 Jan 2024 13:26:34 AEDT ]]> Angiotensin II for the treatment of vasodilatory shock https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:31005 Mon 23 Sep 2019 10:08:51 AEST ]]> Clinical translation of basic science in asthma https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:38612 Mon 22 Apr 2024 15:11:24 AEST ]]> The IARC Perspective on Alcohol Reduction or Cessation and Cancer Risk https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:54723 Mon 11 Mar 2024 11:58:41 AEDT ]]> Nasal high-flow therapy for newborn infants in special care nurseries https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:38591 Fri 21 Jan 2022 09:14:23 AEDT ]]>